EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Yield of family screening for dilated cardiomyopathy: 10-year experience at a multidisciplinary cardiogenetic outpatient clinic

Isabelle P Thierry, Steven A Muller, Annette F Baas, Dennis Dooijes, R Laura E van Loon, Angela E Schoemaker, Pim van der Harst, Marish I F J Oerlemans, Hubert F Baars, Rutger J Hassink, Folkert W Asselbergs, J Peter van Tintelen und 1 weitere

Netherlands Heart Journal · 2025-02 · 33 (2) · 46-54

DOI: 10.1007/s12471-024-01924-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Netherlands Heart Journal, online erschienen am 20.01.2025. Verfasst von Isabelle P Thierry und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HORIZON EUROPE Framework Programme, Netherlands Heart Institute, ZonMw.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Current family screening approaches in dilated cardiomyopathy (DCM) depend on the presence or absence of a familial genetic variant, in which variant pathogenicity (i.e. benign or pathogenic) classification drives screening recommendations. However, this approach has never been systematically evaluated.

Methods

To describe the yield of DCM family screening stratified by variant classification in the Netherlands, we included 358 relatives (mean age ± standard deviation: 44.4 ± 15.9 years at baseline; 52% female; 41% (likely) pathogenic (LP/P) variant carriers from 210 families). Demographics, symptoms and genetic/cardiac test results were obtained. Endpoints were the development of DCM (left ventricular ejection fraction < 50% of non-ischaemic aetiology) or occurrence of major adverse cardiovascular events (MACE) (i.e. heart failure hospitalisation, ventricular arrhythmia or death). Probability of DCM or MACE was assessed with the Kaplan-Meier method.

Results

DCM was present in 32 relatives (9%) (25/32 (78%) with LP/P variant) at baseline and in an additional 10/97 relatives (10%) (9/10 (90%) with LP/P variant) who were re-evaluated during a median follow-up time of 5.0 years (interquartile range: 3.2–7.4). Of the 128 relatives without the familial LP/P variant, none developed DCM. MACE was experienced by 5 relatives (1%) (4/5 (80%) with LP/P variant), all of whom had DCM at the time of the event.

Conclusion

The yield of DCM family screening was ~10% at baseline and another ~10% during 5‑year follow-up. Relatives without the familial LP/P variant could be safely discharged. These results reinforce the use of a genetics-first screening approach in relatives from families with an LP/P variant. This will lower the burden on resources in Dutch hospitals and help allocate resources to those who are most likely to benefit.

Schlagwörter

Stichwörter der Autor:innen

Cardiac screeningCardiac testingCascade screeningCascade testingDCMDilated cardiomyopathyFamily screening

Autor:innen und Institutionen

  • Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands.
  • Netherlands Heart Institute, Utrecht, The Netherlands.
  • Member of the European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart: ERN GUARD-Heart' (ERN GUARDHEART; http://guardheart.ern-net.eu), Utrecht, The Netherlands.
  • Department of Genetics, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.
  • HartKliniek, Almere-Stad, The Netherlands.
  • Institute of Cardiovascular Science, Faculty Netherlands Health Sciences, University College London, London, UK.

Förderung

  • HORIZON EUROPE Framework Programme
  • Netherlands Heart Institute
  • ZonMw

Zitieren

APA

Thierry, I. P., Muller, S. A., Baas, A. F., Dooijes, D., van Loon, R. L. E., Schoemaker, A. E., van der Harst, P., Oerlemans, M. I. F. J., Baars, H. F., Hassink, R. J., Asselbergs, F. W., van Tintelen, J. P., & Te Riele, A. S. J. M. (2025). Yield of family screening for dilated cardiomyopathy: 10-year experience at a multidisciplinary cardiogenetic outpatient clinic. Netherlands Heart Journal, 33(2), 46-54. https://doi.org/10.1007/s12471-024-01924-1

Vancouver

Thierry IP, Muller SA, Baas AF, Dooijes D, van Loon RLE, Schoemaker AE, et al. Yield of family screening for dilated cardiomyopathy: 10-year experience at a multidisciplinary cardiogenetic outpatient clinic. Netherlands Heart Journal. 2025;33(2):46-54. doi:10.1007/s12471-024-01924-1

BibTeX
@article{Thierry2025,
  author = {Thierry, Isabelle P and Muller, Steven A and Baas, Annette F and Dooijes, Dennis and van Loon, R Laura E and Schoemaker, Angela E and van der Harst, Pim and Oerlemans, Marish I F J and Baars, Hubert F and Hassink, Rutger J and Asselbergs, Folkert W and van Tintelen, J Peter and Te Riele, Anneline S J M},
  title = {Yield of family screening for dilated cardiomyopathy: 10-year experience at a multidisciplinary cardiogenetic outpatient clinic},
  journal = {Netherlands Heart Journal},
  year = {2025},
  volume = {33},
  number = {2},
  pages = {46--54},
  doi = {10.1007/s12471-024-01924-1}
}
Kostenlos starten →